PF-07261271 / Pfizer, Roche - LARVOL DELTA

LBL-053, A Novel Anti-TL1A/p40 Bispecific Antibody for the Treatment of Autoimmune Disorders. [WITHDRAWN] (ACR Convergence 2025) - "Ustekinumab, targeting p40 subunit, has demonstrated robust efficacy and approved for IBD...The effect of LBL-053 on inhibiting TL1A-DR3 downstream signaling pathway was comparabile to RVT-3101, but better than MK-7240 and PF-07261271.LBL-053 also significantly blocked IL-23/IL-12Rβ1 interaction... LBL-053 showed dual immunosuppressive functions, simultaneously inhibiting TL1A-DR3 and IL-23/IL-12Rβ1 signaling pathway, indicating promising clinical applications for the treatment of autoimmune diseases."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • CD4 • IFNG • IL12A • IL18 • IL23A • TNFA

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People (clinicaltrials.gov) - P1 | N=35 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People (clinicaltrials.gov) - P1 | N=35 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Nov 2023 ➔ Feb 2024 | Trial primary completion date: Nov 2023 ➔ Feb 2024

Trial completion date • Trial primary completion date

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People (clinicaltrials.gov) - P1 | N=35 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Aug 2024 ➔ Nov 2023 | Trial primary completion date: Aug 2024 ➔ Nov 2023

Trial completion date • Trial primary completion date

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People (clinicaltrials.gov) - P1 | N=51 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People (clinicaltrials.gov) - P1 | N=51 | Not yet recruiting | Sponsor: Pfizer

New P1 trial